OR WAIT 15 SECS
From OncLive, five experts share their perspectives and opinions on the latest research related to triple-negative breast cancer.
Participants include Joyce A. O'Shaughnessy, MD, Baylor-Sammons Cancer Center; Adam M. Brufsky, MD, University of Pittsburg Cancer Institute; Sarah A. Hurvitz, MD, UCLA Jonsson Comprehensive Cancer Center; Kevin M. Kalinsky, MD, Columbia University Medical Center; and Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute.
The experts discuss new data from the European Society for Medical Oncology’s (ESMO) Virtual Congress 2020 and standards of care for early-stage triple-negative breast cancer.
“I think that increasingly for our patients with early-stage triple-negative breast cancer, we treat with neoadjuvant chemotherapy. I think that this is for a number of reasons so that we could see how patients are responding to the treatments that we’re giving,” said Dr. Kalinsky.
Visit OncLive to hear their perspectives.